AntriaBio chooses Louisville, Colorado, for its new research and manufacturing facility

Biopharmaceutical company AntriaBio, Inc. has chosen Louisville, Colorado, for its new manufacturing facility.

AntriaBio will conduct research at the new location, which is approximately 27,000 square feet. The company hopes to develop new treatments for people with diabetes and metabolic diseases, according to a company statement. 

It will also manufacture microspheres for its lead product candidate AB101 at the facility. AB101 is a once-a-week basal insulin treatment for both Type 1 and Type 2 diabetes. The company's product uses a polymer that attaches to the insulin allowing it to slowly dissolve. This product is different than others on the market that need to be taken once or twice a day, Boulder County Business Report stated. The company acquired manufacturing equipment to create the product from its acquisition of PR Pharmaceuticals, Inc, according to a company statement.

AntraBio hopes to develop its product further before taking it to clinical trials next year.

The new facility means the creation of up to 30 new jobs, Boulder County Business Report stated.

Businesses moving into new facilities and creating open positions should partner with technology recruiters to find the most qualified candidates for their new jobs.